Cargando…

Alpha‐1‐antitrypsin in cell and organ transplantation

Limited availability of donor organs and risk of ischemia‐reperfusion injury (IRI) seriously restrict organ transplantation. Therapeutics that can prevent or reduce IRI could potentially increase the number of transplants by increasing use of borderline organs and decreasing discards. Alpha‐1 antitr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berger, Mel, Liu, Mingyao, Uknis, Marc E., Koulmanda, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Minireviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055806/ https://www.ncbi.nlm.nih.gov/pubmed/29607607 http://dx.doi.org/10.1111/ajt.14756

Ejemplares similares

Improving engraftment of hepatocyte transplantation using alpha-1 antitrypsin as an immune modulator
por: Lee, Charlotte, et al.
Publicado: (2019)

Trained immunity in organ transplantation
por: Ochando, Jordi, et al.
Publicado: (2019)

Alpha-1 Antitrypsin for COVID-19 Treatment: Dual Role in Antiviral Infection and Anti-Inflammation
por: Yang, Chengliang, et al.
Publicado: (2020)

Mineralization of alpha-1-antitrypsin inclusion bodies in Mmalton alpha-1-antitrypsin deficiency
por: Callea, Francesco, et al.
Publicado: (2018)

Lung and liver transplantation in patients with alpha-1 antitrypsin deficiency
por: Zamora, Martin R., et al.
Publicado: (2021)

Connexins in endothelial cells as a therapeutic target for solid organ transplantation
por: Jaishankar, Dinesh, et al.
Publicado: (2022)

A Case of Alpha-1 Antitrypsin Deficiency and Organizing Pneumonia
por: Renduchintala, Kavita, et al.
Publicado: (2020)

Gene therapy for alpha 1-antitrypsin deficiency with an oxidant-resistant human alpha 1-antitrypsin
por: Sosulski, Meredith L., et al.
Publicado: (2020)

Alpha-1 Antitrypsin as a Therapeutic Agent for Conditions not Associated with Alpha-1 Antitrypsin Deficiency
por: Wanner, Adam
Publicado: (2015)

Solid organ transplantations and COVID-19 disease
por: Yılmaz, Emine Aylin, et al.
Publicado: (2021)

Impact of tacrolimus intra-patient variability in adverse outcomes after organ transplantation
por: Morais, Maria Clara, et al.
Publicado: (2023)

Kidney disease in non-kidney solid organ transplantation
por: Swanson, Kurtis J
Publicado: (2022)

Women’s health issues in solid organ transplantation: Breast and gynecologic cancers in the post-transplant population
por: Jones-Pauley, Michelle, et al.
Publicado: (2023)

Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency
por: Petrache, Irina, et al.
Publicado: (2009)

The Immunoregulation Effect of Alpha 1-Antitrypsin Prolong β-Cell Survival after Transplantation
por: Wang, Yun, et al.
Publicado: (2014)

Bariatric surgery outcomes following organ transplantation: A review study
por: Kheirvari, Milad, et al.
Publicado: (2022)

Thymosin alpha 1: A comprehensive review of the literature
por: Dominari, Asimina, et al.
Publicado: (2020)

Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications
por: Chapman, Kenneth R, et al.
Publicado: (2018)

Structural characterization and conformational dynamics of alpha-1 antitrypsin pathogenic variants causing alpha-1-antitrypsin deficiency
por: Shaik, Noor Ahmad, et al.
Publicado: (2022)

Influence of tacrolimus metabolism rate on renal function after solid organ transplantation
por: Thölking, Gerold, et al.
Publicado: (2017)

Evolution of liver transplant organ allocation policy: Current limitations and future directions
por: Polyak, Alexander, et al.
Publicado: (2021)

Renal manifestations of hepatitis E among immunocompetent and solid organ transplant recipients
por: Kovvuru, Karthik, et al.
Publicado: (2022)

Recommendations for the Implementation of the Self-Administration of Alpha-1 Antitrypsin
por: Torres-Durán, María, et al.
Publicado: (2023)

Retraction: The Immunoregulation Effect of Alpha 1-Antitrypsin Prolong β-Cell Survival after Transplantation
Publicado: (2018)

Alpha-1 antitrypsin deficiency: outstanding questions and future directions
por: Torres-Durán, María, et al.
Publicado: (2018)

Alpha 1-antitrypsin and survival in hepatocellular carcinoma.
por: Tzonou, A., et al.
Publicado: (1990)

alpha1-Antitrypsin deficiency and hepatocellular cancer.
por: Kew, M. C., et al.
Publicado: (1978)

The prevalence of alpha-1 antitrypsin deficiency in Ireland
por: Carroll, Tomás P, et al.
Publicado: (2011)

Alpha 1-antitrypsin retention in an ectopic liver
por: Dettmer, Matthias, et al.
Publicado: (2011)

Polymorphism of alpha-1-antitrypsin in hematological malignancies
por: Topic, Aleksandra, et al.
Publicado: (2009)

Alpha-1-Antitrypsin in Pathogenesis of Hepatocellular Carcinoma
por: Topic, Aleksandra, et al.
Publicado: (2012)

Alpha-1 Antitrypsin Deficiency: The Learning Goes On
por: Stockley, Robert. A.
Publicado: (2020)

Monocytes and Macrophages in Alpha-1 Antitrypsin Deficiency
por: Belchamber, Kylie B R, et al.
Publicado: (2020)

Alpha-1 Antitrypsin Deficiency: Home Therapy
por: Annunziata, Anna, et al.
Publicado: (2021)

Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma
por: Hanif, Hira, et al.
Publicado: (2022)

The Relationship between Plasma Alpha-1-Antitrypsin Polymers and Lung or Liver Function in ZZ Alpha-1-Antitrypsin-Deficient Patients
por: Sark, Annelot D., et al.
Publicado: (2022)

Chances and risks of sodium-glucose cotransporter 2 inhibitors in solid organ transplantation: A review of literatures
por: Schwarzenbach, Marlene, et al.
Publicado: (2021)

alpha 1-Antitrypsin deficiency and susceptibility to lung disease.
por: Evans, H E, et al.
Publicado: (1979)

Update on and future perspectives for the diagnosis of alpha-1 antitrypsin deficiency in Brazil
por: Jardim, José R, et al.
Publicado: (2021)

Xenogeneic stem cell transplantation: Research progress and clinical prospects
por: Jiang, Lin-Li, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ltjrrgcfcenfb8s2pl9lktgqs4